Osimertinib-induced lymphocytopenia and pneumocystis jirovecii pneumonia

Pulmonology. 2022 Sep-Oct;28(5):403-405. doi: 10.1016/j.pulmoe.2022.04.005. Epub 2022 Jun 11.

Authors

H Takechi¹, H Endoh², Y Hata¹, S Wasamoto¹, S Yanagisawa³

Affiliations

¹ Department of Respiratory Medicine, Saku Central Hospital Advanced Care Center, 3400-28 Nakagomi, Saku-city, Nagano 385-0051, Japan.
² Department of Thoracic Surgery, Saku Central Hospital Advanced Care Center, 3400-28 Nakagomi, Saku-city, Nagano 385-0051, Japan.
³ Department of Respiratory Medicine, Saku Central Hospital Advanced Care Center, 3400-28 Nakagomi, Saku-city, Nagano 385-0051, Japan. Electronic address: yngsw-0829@umin.org.

PMID: 35701337
DOI: 10.1016/j.pulmoe.2022.04.005

No abstract available

Keywords: Epidermal growth factor receptor (EGFR)-mutation; Lung adenocarcinoma; Lymphocytopenia; Osimertinib; Pneumocystis jirovecii pneumonia.

Publication types

Letter

MeSH terms

Acrylamides
Aniline Compounds / adverse effects
Humans
Indoles
Leukopenia*
Lymphopenia* / chemically induced
Pneumonia, Pneumocystis* / diagnosis
Pneumonia, Pneumocystis* / drug therapy
Pyrimidines

Substances

Acrylamides
Aniline Compounds
Indoles
Pyrimidines
osimertinib